Emergex Awarded Innovate UK Grant to Progress its Universal and Pandemic Flu Vaccine

Emergex logo

Oxford, UK, May 14, 2018 / B3C newswire / -- Emergex Vaccines Holding Limited (‘Emergex’), a biotechnology company pioneering a new approach to vaccine development in the field of infectious diseases, today announces that Innovate UK, the UK’s innovation agency, has awarded the company a grant of £979,318 to progress its universal flu vaccine programme through preclinical development.

This grant will cover 70% of the cost of developing Emergex’s flu vaccine programme over a period of two years. It will be used to complete preclinical toxicology and validation studies and the manufacturing of the vaccine in accordance with current Good Manufacturing Practice (cGMP). This will result in clinical batches of the vaccine which are ready for Phase I clinical testing in the first half of 2020.

Emergex’s universal flu vaccine is designed to target components of the influenza virus that are common to all influenza strains. As a result this vaccine will also be suitable to target the outbreak of a new flu pandemic caused by the emergence of a novel form of influenza virus at the time it moves from an animal species into humans. The company’s vaccine is 100% synthetic and delivers highly conserved immunogenic peptide fragments from the flu virus to antigen presenting cells in the skin, eliciting a strong and long-lasting T-cell immune response.

Emergex’s vaccine combines several proprietary technologies to create an immune response based on ‘reverse engineering’. This involves the identification of highly conserved internal peptide fragments from the flu virus, synthesis of these peptide fragments to create a library of 100% synthetic peptide fragments and screening these against blood from flu survivors to see which of the fragments elicit the strongest T-cell immune response. The selected peptide fragments are then combined with a gold nanotechnology carrier system to make an extremely small particle, less than 5 nanometres in diameter, which is ideal for immunization through the skin using a microneedle skin patch, which is less invasive than traditional injection.

The UK government risk register has identified pandemic flu as one of one of the most severe natural challenges likely to affect the UK over the next few years(1). A recent World Health Organization model predicts that pandemic flu could kill an estimated 720,000 people per year and result in economic losses of over US$500bn(2).

Professor Thomas Rademacher, co-founder, CEO and CSO at Emergex commented, “This Innovate UK grant provides endorsement of our flu vaccine programme and reinforces our belief that an innovative approach, using the very latest technologies, could help protect the public from this inevitable epidemic or pandemic health threat.”

In addition to developing a universal flu vaccine, Emergex is also developing a universal Flavivirus vaccine which is cross reactive against Zika, Dengue and Yellow Fever, and a universal Filovirus vaccine which is cross reactive against Ebola and Marburg virus.

 
About Emergex Vaccines Holding Limited
Emergex Vaccines Holding Limited, a UK-based biotechnology company headquartered in Oxford, is pioneering a new approach to vaccine development in order to address some of the world’s most immediate health threats such as Zika, Ebola, pandemic flu and antibiotic resistant bacteria.

It has developed a novel and ground-breaking approach to vaccine manufacturing, using 100% synthetic components to activate T-cells of the immune system to destroy virus-infected human cells. It uses unique technologies together with top-notch science to develop and manufacture vaccines much faster and at a fraction of the cost of traditional vaccines.

Emergex is initially focussed on creating an internationally accessible, clinical grade vaccine repository for use by governments, non-governmental organisations and charities, to act as a first line of defence against existing and newly emerging infectious outbreaks. It also plans to develop commercially marketed vaccines in partnership with pharmaceutical companies to generate future licensing and royalty revenue streams.

Emergex is committed to making a positive impact in the communities that are most affected by these infectious outbreaks, where a lack of affordable and effective treatments adversely impacts health and prosperity. Recently it joined the Social Stock Exchange in London, the world’s first regulated exchange dedicated to businesses and investors seeking to achieve a positive social and environmental impact through their activities.

About Innovate UK
Innovate UK is the UK’s innovation agency. It works with people, companies and partner organisations to find and drive the science and technology innovations that will grow the UK economy.


Contact

Emergex Vaccines Holding Ltd
Storme Moore-Thornicroft, Executive Director
+44 (0) 1235 527589
This email address is being protected from spambots. You need JavaScript enabled to view it.

Media Contacts

Instinctif Partners
Sue Charles / Ashley Tapp
+44 (0)20 7457 2020
This email address is being protected from spambots. You need JavaScript enabled to view it.


References

  1. UK National Risk Register https://www.scribd.com/document/4746228/UK-National-Risk-Register
  2. How large are the expected losses? Bulletin of the World Health Organization 2018;96:129-134. doi: http://www.who.int/bulletin/volumes/96/2/17-199588/en/

 

Cookies make it easier for us to provide you with our services. With the usage of our services you permit us to use cookies.
Ok